# Open Label Extension Study of Epratuzumab in Japanese Systemic Lupus Erythematosus (SLE) Subjects

> **NCT01534403** · PHASE2 · COMPLETED · sponsor: **UCB Pharma** · enrollment: 17 (actual)

## Conditions studied

- Systemic Lupus Erythematosus

## Interventions

- **BIOLOGICAL:** Epratuzumab

## Key facts

- **NCT ID:** NCT01534403
- **Lead sponsor:** UCB Pharma
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2012-01
- **Primary completion:** 2015-02
- **Final completion:** 2015-02
- **Target enrollment:** 17 (ACTUAL)
- **Last updated:** 2016-05-06


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01534403

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01534403, "Open Label Extension Study of Epratuzumab in Japanese Systemic Lupus Erythematosus (SLE) Subjects". Retrieved via AI Analytics 2026-06-01 from https://api.ai-analytics.org/clinical/NCT01534403. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*